Valuation : Orexo AB

Market Cap 53Cr 5.51Cr 4.74Cr 4.46Cr 4.07Cr 7.61Cr 521.38Cr 7.64Cr 20Cr 267Cr 21Cr 20Cr 850.46Cr P/E 2026 *
-1.45x
P/E 2027 * -2.08x
Enterprise Value 42Cr 4.42Cr 3.8Cr 3.57Cr 3.26Cr 6.1Cr 417.83Cr 6.12Cr 16Cr 213.97Cr 17Cr 16Cr 681.56Cr EV / Sales 2026 *
22.3x
EV / Sales 2027 * 14.3x
Free-Float
78.37%
Yield 2026 *
-
Yield 2027 * -
1 day-2.91%
1 week-6.37%
Current month-6.37%
1 month+0.14%
3 months-22.30%
6 months-41.20%
Current year-51.16%
1 week 14.5
Extreme 14.5
16.6
1 month 12.9
Extreme 12.9
16.6
Current year 12.9
Extreme 12.9
36
1 year 12.9
Extreme 12.9
43.4
3 years 9.18
Extreme 9.18
43.4
5 years 8.44
Extreme 8.44
43.4
10 years 8.44
Extreme 8.44
87.9
Manager TitleAgeSince
Chief Executive Officer 54 05/02/2013
Director of Finance/CFO 59 01/09/2022
Chief Tech/Sci/R&D Officer - 01/10/2024
Director TitleAgeSince
Director/Board Member 64 01/01/2002
Director/Board Member 70 11/04/2019
Director/Board Member 62 01/04/2022
Date Insider Type Main position Quantity % Market Cap. Importance
04/09/25 Buy

Chief Executive Officer

6 0.0000%
04/09/25 Free

Chief Executive Officer

1,393 0.0040%
03/09/25 Free 149 0.0004% -
Change 5-day change 1-year change 3-year change Capi.($)
-2.91%-6.37%-40.73%-16.67% 5.53Cr
-1.32%+1.33%+77.46%+41.17% 37TCr
-0.55%-2.81%+21.77%-19.32% 6.86TCr
-0.51%+4.59%+47.06%+168.63% 1.25TCr
-0.56%-10.27%-8.78%-9.42% 806.4Cr
-1.85%-3.41%-22.16%+4.17% 503.58Cr
-0.86%-4.95%-32.18%+19.51% 450.91Cr
-1.39%-4.45%-34.69%-0.21% 306.95Cr
-1.00%-0.46%-5.37%+37.45% 253.03Cr
-0.77%-4.73%-24.93%-17.26% 200.07Cr
Average -1.19%-0.70%-2.26%+20.81% 4.77TCr
Weighted average by Cap. -1.20%+0.44%+63.51%+33.82%

Financials

2026 *2027 *
Net sales 1.9Cr 19.81L 17.04L 16.02L 14.63L 27.36L 19Cr 27.45L 73.44L 9.59Cr 74.4L 72.77L 31Cr 2.7Cr 28.15L 24.21L 22.77L 20.79L 38.88L 27Cr 39L 1.04Cr 14Cr 1.06Cr 1.03Cr 43Cr
Net income -38Cr -3.91Cr -3.36Cr -3.16Cr -2.89Cr -5.4Cr -369.8Cr -5.42Cr -14Cr -189.37Cr -15Cr -14Cr -603.21Cr -27Cr -2.82Cr -2.43Cr -2.28Cr -2.08Cr -3.89Cr -266.75Cr -3.91Cr -10Cr -136.6Cr -11Cr -10Cr -435.11Cr
Net Debt -10Cr -1.09Cr -94.16L -88.56L -80.84L -1.51Cr -103.54Cr -1.52Cr -4.06Cr -53Cr -4.11Cr -4.02Cr -168.9Cr -14Cr -1.49Cr -1.28Cr -1.21Cr -1.1Cr -2.06Cr -141.02Cr -2.07Cr -5.53Cr -72Cr -5.6Cr -5.48Cr -230.02Cr
Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
61
Date Price Change Volume
07/26/07 SEK 14.70 -2.91% 37,583
04/26/04 SEK 15.14 -1.69% 19,314
03/26/03 SEK 15.40 +1.05% 22,080
02/26/02 SEK 15.24 +1.20% 13,800
01/26/01 SEK 15.06 -4.08% 1,54,190
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!